Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY69.45 CNY
Change Today 0.00 / 0.00%
Volume 0.0
000513 On Other Exchanges
Symbol
Exchange
Shenzhen
Hong Kong
Frankfurt
As of 3:00 AM 08/10/15 All times are local (Market data is delayed by at least 15 minutes).

livzon pharmaceutical grou-a (000513) Snapshot

Open
CNY68.00
Previous Close
CNY53.42
Day High
CNY70.33
Day Low
CNY66.00
52 Week High
05/27/15 - CNY76.49
52 Week Low
12/23/14 - CNY36.35
Market Cap
18.1B
Average Volume 10 Days
0.0
EPS TTM
CNY1.46
Shares Outstanding
250.1M
EX-Date
08/14/15
P/E TM
36.5x
Dividend
CNY0.08
Dividend Yield
0.11%
Current Stock Chart for LIVZON PHARMACEUTICAL GROU-A (000513)

Related News

No related news articles were found.

livzon pharmaceutical grou-a (000513) Related Businessweek News

No Related Businessweek News Found

livzon pharmaceutical grou-a (000513) Details

Livzon Pharmaceutical Group Inc. engages in the research and development, production, and sale of pharmaceutical products in the People’s Republic of China. Its products primarily include Chinese and Western drug preparation products, such as Shengqi Fuzheng Injection, a series of Bismuth Potassium Citrate Granules products, anti-viral granules, Urofollitropin for injection, Menotropins for injection, Ilaprazole, Voriconazole for injection, mouse nerve growth factor for injection, and Leuprorelin Acetate Microspheres for injection. The company’s products also comprise bulk medicines and intermediates, including Mevastatin, Colistin, Phenylalanine, Ceftriaxone Sodium, Cefuroxime Sodium, and Cefodizime Sodium; and diagnostic reagent products, such as ELISA HIV testing reagent, MYCOII testing reagent, and TPPA testing reagent. In addition, the company provides chemical drugs, biochemical drugs, microbiological preparations, and antibiotics; polypeptide bulk medicines; diagnostic reagents and equipment; human menopausal gonadotropin and human chorionic gonadotropin medicines; Omeprazole Sodium for injection; Ranitidine Bismuth Citrate tablets; Valaciclovir Hydrochloride tablets; Fluvoxamine Maleate tablet; Perospirone Hydrochloride tablets; and Prostant used for the treatment of clearing away heat evil and promoting diuresis. Further, it offers specialist bulk medicines and intermediates, such as fermented antibiotics, sterile cephalosporins, and hypolipidemic stantins. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China.

5,423 Employees
Last Reported Date: 08/26/15
Founded in 1985

livzon pharmaceutical grou-a (000513) Top Compensated Officers

Vice Chairman, President, Member of Nominatio...
Total Annual Compensation: CNY790.6K
Chief Financial Officer and Vice President
Total Annual Compensation: CNY529.4K
Vice President and Executive Director
Total Annual Compensation: CNY589.3K
Chief Supervisor of the Legal Supervision Hea...
Total Annual Compensation: CNY294.8K
Company Secretary
Total Annual Compensation: CNY232.9K
Compensation as of Fiscal Year 2014.

livzon pharmaceutical grou-a (000513) Key Developments

Livzon Pharmaceutical Group Inc. Announces Change of Address

At the 14th meeting of the eighth session of the board of directors of Livzon Pharmaceutical Group Inc. held on August 26, 2015, the Board proposed to change the registered address of the company from 'Administration and Research Building, 38 Chuangye North Road, Shuanglin Pian Area, Liangang Industrial Zone, Hongqi Town, Jinwan District, Zhuhai City' to 'Administration Building, 38 Chuangye North Road, Jinwan District, Zhuhai City'.

Livzon Pharmaceutical Group Inc. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

Livzon Pharmaceutical Group Inc. reported unaudited consolidated earnings results for the six months ended June 30, 2015. The company reported total income of RMB 3,115,403,701.91, operating profit of RMB 377,369,501.52, profit before income tax of RMB 449,569,149.90, net profit attributable to the shareholders of the parent company of RMB 340,843,355.48 or RMB 1.14 per diluted share against total income of RMB 2,628,474,326.38, operating profit of RMB 344,869,755.57, profit before income tax of RMB 367,217,199.76, net profit attributable to the shareholders of the parent company of RMB 290,934,055.78 or RMB 0.98 per diluted share a year ago. Net cash flows from operating activities was RMB 233,851,215.94 against RMB 203,575,208.54 a year ago. Cash paid for acquisition of fixed assets, intangible assets and other long-term assets was RMB 227,930,964.17 against RMB 361,186,124.08 a year ago.

Livzon Pharmaceutical Group Inc. to Report First Half, 2015 Results on Aug 27, 2015

Livzon Pharmaceutical Group Inc. announced that they will report first half, 2015 results on Aug 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
000513:CH CNY69.45 CNY 0.00

000513 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 000513.
View Industry Companies
 

Industry Analysis

000513

Industry Average

Valuation 000513 Industry Range
Price/Earnings 35.7x
Price/Sales 3.4x
Price/Book 4.9x
Price/Cash Flow 23.0x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIVZON PHARMACEUTICAL GROU-A, please visit www.livzon.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.